shivaani kummar ohsu email

Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . , 'Bal0891' 1 < < < - And to train and inspire the next generation of doctors and scientists. In Brief. Today is a global celebration of giving an opportunity to support the causes that matter the most to you. She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. Try restaurant style recipes at home. February 17, 2023. condition, procedure, doctor name. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU Neoadjuvant nivolumab shows long-term benefit in NSCLC Visit thebilling andinsurancesection of our sitefor more information. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed 2001-2023 OHSU. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Tom Sellers named lead research officer at OHSU Knight Cancer Institute lions led by donkeys for and against. Our ability to move these projects forward and to take on new projects is limited by the available resources. Shivaani Kummar M.D., FACP | Health care provider | OHSU A Novel Artificial Intelligence-Powered Method for Prediction of Early Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. Sort by citations Sort by year Sort by title. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Support the Abortion Care and Training Fund. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for OHSU Foundation P.O. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. Select a country/territory to view shared publications and projects. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Email: trials@ohsu.edu Call: 503-494-1080 The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Stat4Onc Annual Symposium (2022) - University Of Connecticut February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Shivaani Kummar - Professor of Medicine - Stanford - LinkedIn These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Shivaani Kummar | Stanford Health Care NPI Lookup NPI Database. shivaani kummar ohsu email Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. Clinical Activity of the -Secretase Inhibitor PF-03084014 in Adults Share on print. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. . OHSU is an equal opportunity affirmative action institution. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Keep me signed in. Clinical trials Drug development oncology. My patients. Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. It is a privilege to be able to work in this field. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. Dr. (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. OHSU is an equal opportunity affirmative action institution. (h.c.), Ph.D., FAACR. Press Release: Husband-Wife Team From Stanford - The Lund Report Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . The couple says their ultimate goal is to develop new effective therapies for cancer. These topic labels come from the works of this person. OHSU is an equal opportunity affirmative action institution. OHSU is an equal opportunity affirmative action institution. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. 2001-2023 OHSU. Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Dr. Shivaani Kummar, MD, Medical Oncology Specialist - Portland, OR